Healius stock gained 1.23 percent after Agilex sale

Published on 10/07/2026 at 01:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healius stock was last at AUD 0.41 on ASX on October 6, 2026, while FY2026 adjusted EBIT reached AUD 30.2 million. Agilex adds AUD 160 million of deal value.

Healius, AU0000033359, Illustration mit AI erstellt.

Healius stock (ISIN AU0000033359) gained 1.23 percent to AUD 0.41 on the ASX on October 6, 2026, with 4,501,124 shares traded. The move followed the September 25 agreement to sell Agilex Biolabs to Novotech, a transaction that sharpens the group's focus on Australian pathology.

AUD 160 million sale reshapes Healius

According to Business News Australia on September 25, 2026, Healius agreed to sell Agilex for an enterprise value of AUD 160 million. The deal is expected to provide AUD 155 million in net cash after separation and transaction costs, subject to Foreign Investment Review Board and Australian Competition and Consumer Commission approval.

The agreed value equals 19.8 times Agilex's FY2026 reported EBITDA of AUD 10.7 million. Agilex generated FY2026 revenue of AUD 43.6 million and EBIT of AUD 6.4 million, making the disposal a material transaction relative to Healius' remaining pathology business.

FY2026 figures show a mixed turnaround

Healius' FY2026 adjusted revenue rose 2.1 percent to AUD 1.373 billion, while adjusted EBITDA increased 8.1 percent to AUD 258.6 million. Adjusted EBIT climbed from AUD 17.1 million in FY2025 to AUD 30.2 million in FY2026, according to BBRW in its September 29, 2026 report.

The figures put the sale in context: Agilex delivered AUD 6.4 million of FY2026 EBIT, while the wider group produced AUD 30.2 million. The disposal can therefore improve balance-sheet flexibility, but the core earnings recovery still depends on pathology volumes, labor costs and collection-center productivity.

Analysts trim targets after disposal

FNArena reported on October 5, 2026, that Morgans retained its Hold rating while cutting its target to AUD 0.40 from AUD 0.43. Macquarie kept a Neutral view and reduced its target by AUD 0.03 to AUD 0.43, citing wage pressure, subdued general-practitioner attendances and a delayed margin recovery.

The analyst response highlights the central tension. Agilex has been sold at a high operating multiple, but the smaller Healius will need to convert the proceeds and its pathology strategy into sustained margin improvement before the higher targets become relevant.

Healius stock stays below its yearly high

Healius stock was last at AUD 0.41 on the ASX on October 6, 2026, at 61.7 percent below its 52-week high of AUD 1.07 and above its 52-week low of AUD 0.30. Its market capitalization was AUD 297.7 million on that date.